Kenneth Hillan Email Address

Head of Therapeutics

Achaogen, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterials to treat multi-drug resistant (MDR) gram-negative infections. The Company is developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant enterobacteriaceae (CRE). Plazomicin is an aminoglycoside designed to overcome clinically relevant aminoglycoside resistance mechanisms. In addition, its research and development pipeline includes two programs that specifically target Pseudomonas aeruginosa or Acinetobacter baumannii infections: a program to discover and develop small molecule inhibitors of LpxC, which is an enzyme essential for the synthesis of the outer membrane of gram-negative bacteria, and a therapeutic antibody program. Its development plan for plazomicin includes over two Phase III clinical trials.

Head of Therapeutics at 23andMe, the leading personal genetics company committed to helping people access, understand and benefit from the human genome. Previously: CEO of Achaogen, an innovative antibacterial agents to address multidrug resistant (MDR) gram-negative infections SVP, Development at Genentech, Inc. Clinical Summary: MRC French Exchange Fellow - 1985-6 Surgeon, specializing in general and transplant surgery (Western Infirmary, Glasgow and University of Glasgow, Scotland) - 1986-9 Surgical Pathologist (Western Infirmary, Glasgow and University of Glasgow, Scotland) - 1989-1994 Specialties: Fellow of the Royal College of Surgeons (FRCS) Fellow of the Royal College of Pathologists (FRCPath)